Although preclinical evidence suggested a potent synergistic effect of berzosertib and cisplatin on cancer cell survival, particularly in tumors with TP53 mutations, this was not observed with the berzosertib and cisplatin doses utilized in this study18–20. The gene discussed is TP53; the disease is cancer.